Abstract:Tumor immunotherapy has profoundly transformed the therapeutic landscape for many advanced malignancies. However, with the increasing clinical application of immune checkpoint inhibitors (ICI), a spectrum of immune-related adverse events (irAEs) has emerged, among which ICI-induced colitis is one of the most common gastrointestinal irAEs. In severe cases, it can lead to treatment interruption and even patient death. The current mainstay treatments, glucocorticoids and biological agents, are often associated with inconsistent efficacy, significant side effects, and a risk of recurrence. In recent years, traditional Chinese medicine (TCM) has demonstrated unique advantages in treating ICI-induced colitis through its multi-target and holistic regulatory approach. In this article, based on advanced domestic and international literature, we systematically elaborated the potential mechanisms of traditional Chinese medicine and its active components in treatment of ICI-induced colitis, from the aspects of regulating regulatory T cell/T helper 17 cell balance, modulating macrophage polarization, restoring T helper 1 cell/T helper 2 cell balance, and improving gut microbiota, aiming to provide new ideas and references for alleviating irAEs and improving patient′s quality of life.